Nidhi Sandal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nidhi Sandal has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Mahendra Yadav
Division of CBRN Defence, Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, Ministry of Defence, New Delhi, India
8 shared publicationsMeenakshi Kanwar Chauhan
Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
5 shared publicationsVivek Kumar
Division of CBRN Defence, Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, Ministry of Defence, New Delhi, India
5 shared publicationsDharam Pal Pathak
Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
4 shared publicationsPooja Sharma
Division of CBRN Defence, Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, New Delhi 110054, India
3 shared publicationsAjay K. Singh
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, New Delhi,India
2 shared publications
Latest Publications
- 4 June 2025
- Published by Springer Nature in Toxicology and Environmental Health Sciences
- Vol. 17 (2) , 239-254
Assessment of potential effects of Spirulina (Arthrospira platensis) as a bio-remedial agent against strontium and thallium contamination
- 4 June 2025
- Published by Springer Nature in Toxicology and Environmental Health Sciences
- Vol. 17 (2) , 239-254
Assessment of potential effects of Spirulina (Arthrospira platensis) as a bio-remedial agent against strontium and thallium contamination
- Open Access
- 7 April 2025
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 10 (2) , 121-126
Commercialisation of Innovations: A Case Study of Liposomal Formulations
Liposomes are the potential drug delivery systems for various therapeutic categories. During the past 60 years, researchers have explored this drug delivery system which has resulted in a large pool of documents in terms of patents and publications. The paper’s objective is to understand why after 60 years of extensive research with more than 50,000 patent documents and 35,000 research publications, only 17 products based on liposomes are commercially available. After detailed analysis, the authors found that the research publications and patent documents are primarily focused on the basic research aspects and have limited participation from the industry. Therefore, in this paper, it has been emphasised how the research projects on liposomes must re-orient its focus so that it leads to the commercialisation of liposomes. This paper also provides a comprehensive analysis of challenges and opportunities for researchers concerning various research areas of liposomes like manufacturing techniques, characterisations, stability, storage, pre-clinical and clinical evaluations, regulatory requirements as well as pharmaco-economic analysis.
- 7 April 2025
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 10 (2) , 121-126
Open AccessCommercialisation of Innovations: A Case Study of Liposomal Formulations
Liposomes are the potential drug delivery systems for various therapeutic categories. During the past 60 years, researchers have explored this drug delivery system which has resulted in a large pool of documents in terms of patents and publications. The paper’s objective is to understand why after 60 years of extensive research with more than 50,000 patent documents and 35,000 research publications, only 17 products based on liposomes are commercially available. After detailed analysis, the authors found that the research publications and patent documents are primarily focused on the basic research aspects and have limited participation from the industry. Therefore, in this paper, it has been emphasised how the research projects on liposomes must re-orient its focus so that it leads to the commercialisation of liposomes. This paper also provides a comprehensive analysis of challenges and opportunities for researchers concerning various research areas of liposomes like manufacturing techniques, characterisations, stability, storage, pre-clinical and clinical evaluations, regulatory requirements as well as pharmaco-economic analysis.
- 1 March 2025
- Published by IOP Publishing in Journal of Radiological Protection
- Vol. 45 (1) , 011002
Optimizing Ca-DTPA/Zn-DTPA therapy for internal decorporation: transitioning from intravenous to oral route with insights on safety and toxicity
Ca-DTPA and Zn-DTPA are the decorporating agents approved by the USFDA for removing plutonium, americium, or curium from the subjects known or suspected to be contaminated with these radionuclides. Ca-DTPA and Zn-DTPA are well-known chelating agents with a strong affinity for many bivalent, trivalent, and certain tetravalent metal ions, including plutonium (Pu+4) and thorium (Th+4). The major problem associated with Ca-DTPA and Zn-DTPA therapy is that the only approved route of administration is intravenous or inhalation due to its extremely poor bioavailability. Both these drugs belong to BCS class III drugs with high solubility and low permeability. Researchers are exploring various approaches to make these drugs bioavailable via alternate routes, especially the oral route. This will enable pre-hospital care, better patient compliance, and minimize its clinically significant side effect of electrolyte imbalance. The present paper highlights the practical feasibility and challenges of establishing an oral route for delivering Ca-DTPA and Zn-DTPA with the research around it. Also, the paper highlights the importance of establishing an oral dose and the dosing schedule for Ca-DTPA and Zn-DTPA before plunging into its formulation development. These advancements underline the potential of orally administered chelating agents and alternative delivery methods in addressing the limitations of current intravenous formulations and improving accessibility and patient outcomes.
- 1 March 2025
- Published by IOP Publishing in Journal of Radiological Protection
- Vol. 45 (1) , 011002
Optimizing Ca-DTPA/Zn-DTPA therapy for internal decorporation: transitioning from intravenous to oral route with insights on safety and toxicity
Ca-DTPA and Zn-DTPA are the decorporating agents approved by the USFDA for removing plutonium, americium, or curium from the subjects known or suspected to be contaminated with these radionuclides. Ca-DTPA and Zn-DTPA are well-known chelating agents with a strong affinity for many bivalent, trivalent, and certain tetravalent metal ions, including plutonium (Pu+4) and thorium (Th+4). The major problem associated with Ca-DTPA and Zn-DTPA therapy is that the only approved route of administration is intravenous or inhalation due to its extremely poor bioavailability. Both these drugs belong to BCS class III drugs with high solubility and low permeability. Researchers are exploring various approaches to make these drugs bioavailable via alternate routes, especially the oral route. This will enable pre-hospital care, better patient compliance, and minimize its clinically significant side effect of electrolyte imbalance. The present paper highlights the practical feasibility and challenges of establishing an oral route for delivering Ca-DTPA and Zn-DTPA with the research around it. Also, the paper highlights the importance of establishing an oral dose and the dosing schedule for Ca-DTPA and Zn-DTPA before plunging into its formulation development. These advancements underline the potential of orally administered chelating agents and alternative delivery methods in addressing the limitations of current intravenous formulations and improving accessibility and patient outcomes.
- 29 December 2023
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 50 (1) , 78-88
Enhancing oral bioavailability of Ca-DTPA by self double emulsifying drug delivery system (SDEDDS)
ObjectiveBCS class III drug (highly soluble, poorly permeable) possesses low oral bioavailability. The research work highlights the utility of self-double emulsifying drug delivery system (SDEDDS) which are stable isotropic mixture of w/o primary emulsion and hydrophilic surfactants for improving oral bioavailability of Ca-DTPA (Calcium diethylenetriamine pentaacetate). Upon oral administration, SDEDDS rapidly emulsifies into w/o/w double emulsions in the aqueous gastrointestinal environment, with hydrophilic drugs entrapped inside oil reservoirs.MethodsSDEDDS formulation was successfully developed using excipients, that is, medium chain triglycerides, oleic acid, phospholipids, Span 80, Tween 80 using double emulsification technique.ResultsThe optimized formulation F4 (Aq. phase: 11.6%w,w; MCT & oleic acid: 70.9%w/w; Span 80:17.5%w/w; Lecithin:16%w/w and Tween 80 (10%w/w)) appeared bright yellow liquid which upon dilution appeared milky white within 2 min, droplet size (501.7 nm), pdi value (0.044), zeta potential (-52 mV), entrapment efficiency (79.6 +/- 1.63), viscosity (72.2 +/- 1.8 mpA.s), significant high cumulative in vitro drug permeation (CDP) and 2.17-fold increase in apparent permeability coefficient. Pharmacokinetic studies in rats showed 1.17-fold increases in AUC of F4 and comparatively higher plasma levels (Cmax) compared with pure drug administered orally. The Absolute (OF4, OD) and Relative bioavailability was found to be 14.52%, 12.35%, and 117.47%, respectively.ConclusionThe present studies have clearly demonstrated that SDEDDS could readily form w/o/w double emulsions in vivo with enhanced in vitro and in vivo oral bioavailability. Therefore, considerable augmentation in the rate and extent of oral drug absorption ratified the better performance of the SDEDDS in enhancing the bioavailability of Ca-DTPA.
- 29 December 2023
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 50 (1) , 78-88
Enhancing oral bioavailability of Ca-DTPA by self double emulsifying drug delivery system (SDEDDS)
ObjectiveBCS class III drug (highly soluble, poorly permeable) possesses low oral bioavailability. The research work highlights the utility of self-double emulsifying drug delivery system (SDEDDS) which are stable isotropic mixture of w/o primary emulsion and hydrophilic surfactants for improving oral bioavailability of Ca-DTPA (Calcium diethylenetriamine pentaacetate). Upon oral administration, SDEDDS rapidly emulsifies into w/o/w double emulsions in the aqueous gastrointestinal environment, with hydrophilic drugs entrapped inside oil reservoirs.MethodsSDEDDS formulation was successfully developed using excipients, that is, medium chain triglycerides, oleic acid, phospholipids, Span 80, Tween 80 using double emulsification technique.ResultsThe optimized formulation F4 (Aq. phase: 11.6%w,w; MCT & oleic acid: 70.9%w/w; Span 80:17.5%w/w; Lecithin:16%w/w and Tween 80 (10%w/w)) appeared bright yellow liquid which upon dilution appeared milky white within 2 min, droplet size (501.7 nm), pdi value (0.044), zeta potential (-52 mV), entrapment efficiency (79.6 +/- 1.63), viscosity (72.2 +/- 1.8 mpA.s), significant high cumulative in vitro drug permeation (CDP) and 2.17-fold increase in apparent permeability coefficient. Pharmacokinetic studies in rats showed 1.17-fold increases in AUC of F4 and comparatively higher plasma levels (Cmax) compared with pure drug administered orally. The Absolute (OF4, OD) and Relative bioavailability was found to be 14.52%, 12.35%, and 117.47%, respectively.ConclusionThe present studies have clearly demonstrated that SDEDDS could readily form w/o/w double emulsions in vivo with enhanced in vitro and in vivo oral bioavailability. Therefore, considerable augmentation in the rate and extent of oral drug absorption ratified the better performance of the SDEDDS in enhancing the bioavailability of Ca-DTPA.
- 16 October 2023
- Published by IOP Publishing in Journal of Radiological Protection
- Vol. 43 (4) , 044001
Challenges in development and management of orphan drugs—a case study of Prussian blue insoluble
Prussian blue insoluble (PB) is an antidote for decorporation of radioactive and non-radioactive isotopes of thallium and cesium. Its dosage in the form of capsules, Radiogardase-Cs, is a United States Food and Drug Administration approved formulation since 2003. In India and many other countries, this drug is not available and in case of requirement it is imported from US or Europe. The author has worked extensively to make PB capsules available in India. The drug was recently approved by the Indian drug regulatory agency, Central Drugs Standard Control Organisation and is now available commercially in India. However this drug needs special attention as it is an orphan drug with limited requirement. The post-approval phase of this drug poses a different set of challenges and the author has highlighted some key issues with probable approaches for post-approval product management.
- 16 October 2023
- Published by IOP Publishing in Journal of Radiological Protection
- Vol. 43 (4) , 044001
Challenges in development and management of orphan drugs—a case study of Prussian blue insoluble
Prussian blue insoluble (PB) is an antidote for decorporation of radioactive and non-radioactive isotopes of thallium and cesium. Its dosage in the form of capsules, Radiogardase-Cs, is a United States Food and Drug Administration approved formulation since 2003. In India and many other countries, this drug is not available and in case of requirement it is imported from US or Europe. The author has worked extensively to make PB capsules available in India. The drug was recently approved by the Indian drug regulatory agency, Central Drugs Standard Control Organisation and is now available commercially in India. However this drug needs special attention as it is an orphan drug with limited requirement. The post-approval phase of this drug poses a different set of challenges and the author has highlighted some key issues with probable approaches for post-approval product management.
- Open Access
- 24 July 2023
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 47 (1) , 1-14
Toxicity and antidotal treatment by synthesized and optimized ferric(III) hexacyanoferrate(II) for thallium
Background: The active pharmaceutical ingredient (API) of USFDA-approved Radiogardase®-Cs capsule is ferric(III) hexacyanoferrate(II) which is commonly known as Prussian blue insoluble (PB). It enhances the elimination of radioactive or non-radioactive caesium/thallium (Cs(I)/Tl(I)) from the body. The API of Radiogardase®-Cs capsules is not available commercially; therefore, in-house API was synthesized and evaluated. The present study includes toxicity evaluation and in vivo Tl(I) removal efficacy of in-house synthesized and optimized PB prepared by direct (PB-1) and indirect (PB-2) synthesis methods. PB-1 and PB-2 were evaluated for acute and sub-acute oral toxicity in accordance with OECD guidelines in rats. Results: No significant changes were observed in treatment groups as compared to the control group of acute and sub-acute oral toxicity studies. The food intake, water consumption, body weight, clinical signs, organ weight and histopathological, biochemical and haematological parameters were monitored. The study found no evidence of mortality. The results indicated that the synthesized PB-1 and PB-2 were safe. As a result, the study further examined PB-1 and PB-2 for removal of Tl(I) in rats. A significant increase in Tl(I) removal was observed when PB-1 and PB-2 were administered orally to rats in comparison to no treatment group. The Tl(I) removal efficacy of PB-1 and PB-2 was comparable to Radiogardase®-Cs treated group. Results showed reduction in the body burden of Tl(I) as well as a higher level of elimination of Tl(I) in faeces and urine. Conclusions: The study provides substantial support regarding Tl(I) removal efficacy and safety of in-house synthesized PB-1 and PB-2 which can be used for formulation development.
- 24 July 2023
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 47 (1) , 1-14
Open AccessToxicity and antidotal treatment by synthesized and optimized ferric(III) hexacyanoferrate(II) for thallium
Background: The active pharmaceutical ingredient (API) of USFDA-approved Radiogardase®-Cs capsule is ferric(III) hexacyanoferrate(II) which is commonly known as Prussian blue insoluble (PB). It enhances the elimination of radioactive or non-radioactive caesium/thallium (Cs(I)/Tl(I)) from the body. The API of Radiogardase®-Cs capsules is not available commercially; therefore, in-house API was synthesized and evaluated. The present study includes toxicity evaluation and in vivo Tl(I) removal efficacy of in-house synthesized and optimized PB prepared by direct (PB-1) and indirect (PB-2) synthesis methods. PB-1 and PB-2 were evaluated for acute and sub-acute oral toxicity in accordance with OECD guidelines in rats. Results: No significant changes were observed in treatment groups as compared to the control group of acute and sub-acute oral toxicity studies. The food intake, water consumption, body weight, clinical signs, organ weight and histopathological, biochemical and haematological parameters were monitored. The study found no evidence of mortality. The results indicated that the synthesized PB-1 and PB-2 were safe. As a result, the study further examined PB-1 and PB-2 for removal of Tl(I) in rats. A significant increase in Tl(I) removal was observed when PB-1 and PB-2 were administered orally to rats in comparison to no treatment group. The Tl(I) removal efficacy of PB-1 and PB-2 was comparable to Radiogardase®-Cs treated group. Results showed reduction in the body burden of Tl(I) as well as a higher level of elimination of Tl(I) in faeces and urine. Conclusions: The study provides substantial support regarding Tl(I) removal efficacy and safety of in-house synthesized PB-1 and PB-2 which can be used for formulation development.
- Open Access
- 7 June 2023
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 8 (2) , 131-136
Physicochemical Characterisation of Commercially Available Prussian Blue Insoluble Samples and Its Comparison with Radiogardase Cs
The physicochemical properties of insoluble Prussian blue (PB) play an important role in its thallium binding ability. Therefore, the present study aimed to characterise various physicochemical parameters of PB available commercially and compare them with the USFDA-approved Radiogardase ® -Cs. In addition, PB was synthesised by indirect and direct methods. PB samples and Radiogardase®-Cs were analysed for various parameters like particle size, moisture content, and thermogravimetric analysis (TGA) and correlated with its Maximum Binding Capacity (MBC) for thallium. Radiogardase ® -Cs showed the highest MBC of 238 mg/g for thallium with D 90 of 785 μm and moisture content of 23.24 %. The MBC of other PB samples was found to be significantly lower than Radiogardase ® -Cs which was found to be directly proportional to the moisture content. However, other parameters like particle size, and iron content vary significantly but no correlation was observed with MBC for thallium. This finding suggests that moisture content and MBC are extremely important parameters for optimising the PB to achieve desirable pharmacological efficacy for removing thallium in vivo.
- 7 June 2023
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 8 (2) , 131-136
Open AccessPhysicochemical Characterisation of Commercially Available Prussian Blue Insoluble Samples and Its Comparison with Radiogardase Cs
The physicochemical properties of insoluble Prussian blue (PB) play an important role in its thallium binding ability. Therefore, the present study aimed to characterise various physicochemical parameters of PB available commercially and compare them with the USFDA-approved Radiogardase ® -Cs. In addition, PB was synthesised by indirect and direct methods. PB samples and Radiogardase®-Cs were analysed for various parameters like particle size, moisture content, and thermogravimetric analysis (TGA) and correlated with its Maximum Binding Capacity (MBC) for thallium. Radiogardase ® -Cs showed the highest MBC of 238 mg/g for thallium with D 90 of 785 μm and moisture content of 23.24 %. The MBC of other PB samples was found to be significantly lower than Radiogardase ® -Cs which was found to be directly proportional to the moisture content. However, other parameters like particle size, and iron content vary significantly but no correlation was observed with MBC for thallium. This finding suggests that moisture content and MBC are extremely important parameters for optimising the PB to achieve desirable pharmacological efficacy for removing thallium in vivo.
- 24 May 2023
- Published by Springer Nature in BioMetals
- Vol. 36 (5) , 1125-1140
In vitro and in vivo removal efficacy of insoluble Prussian blue in combination with calcium polystyrene sulfonate for thallium
The similarities between thallium and potassium have suggested the use of calcium polystyrene sulfonate (CPS), an oral ion exchange resin, as a potential agent against thallium intoxication. Therefore, the study was an attempt to evaluate the efficacy of CPS and Prussian blue when given alone or in combination against thallium toxicity. The effect on binding capacity was investigated in terms of contact time, amount of CPS, influence of pH, simulated physiological solutions and interference of potassium ions. Also, rats were given single dose of thallium chloride (20 mg kg−1) and the treatment with PB and CPS was given for 28 days as CPS 30 g kg−1, orally, twice a day, PB 3 g kg−1, orally, twice a day and their combination. The effect of antidotal treatment was evaluated by calculating the thallium levels in various organs, blood, urine and feces. The results of the in vitro study indicated exceedingly quick binding in the combination of CPS and PB as compared to PB alone. Also, it was found that the binding capacity at pH 2.0 was considerably increased for PB with CPS (184.656 mg g−1) as compared to PB (37.771 mg g−1). Furthermore, statistically significant results were obtained in the in vivo study as after 7th day, thallium levels in blood of rats treated with combination were reduced by 64% as compared to control group and 52% as compared to alone PB treated group. Also, Tl retention in liver, kidney, stomach, colon and small intestine of combination treated rats was significantly reduced to 46%, 28%, 41%, 32% and 33% respectively, as compared to alone PB treated group. These findings demonstrate this as a good antidotal option against thallium intoxication.
- 24 May 2023
- Published by Springer Nature in BioMetals
- Vol. 36 (5) , 1125-1140
In vitro and in vivo removal efficacy of insoluble Prussian blue in combination with calcium polystyrene sulfonate for thallium
The similarities between thallium and potassium have suggested the use of calcium polystyrene sulfonate (CPS), an oral ion exchange resin, as a potential agent against thallium intoxication. Therefore, the study was an attempt to evaluate the efficacy of CPS and Prussian blue when given alone or in combination against thallium toxicity. The effect on binding capacity was investigated in terms of contact time, amount of CPS, influence of pH, simulated physiological solutions and interference of potassium ions. Also, rats were given single dose of thallium chloride (20 mg kg−1) and the treatment with PB and CPS was given for 28 days as CPS 30 g kg−1, orally, twice a day, PB 3 g kg−1, orally, twice a day and their combination. The effect of antidotal treatment was evaluated by calculating the thallium levels in various organs, blood, urine and feces. The results of the in vitro study indicated exceedingly quick binding in the combination of CPS and PB as compared to PB alone. Also, it was found that the binding capacity at pH 2.0 was considerably increased for PB with CPS (184.656 mg g−1) as compared to PB (37.771 mg g−1). Furthermore, statistically significant results were obtained in the in vivo study as after 7th day, thallium levels in blood of rats treated with combination were reduced by 64% as compared to control group and 52% as compared to alone PB treated group. Also, Tl retention in liver, kidney, stomach, colon and small intestine of combination treated rats was significantly reduced to 46%, 28%, 41%, 32% and 33% respectively, as compared to alone PB treated group. These findings demonstrate this as a good antidotal option against thallium intoxication.
- 1 February 2023
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 49 (2) , 149-158
Oral formulation of Prussian blue with improved efficacy for prophylactic use against thallium
Objective The present study is aimed to enhance the efficacy of Insoluble Prussian blue (PB) in stomach. PB formulation was developed comprising of PB in combination with pH modifying agents particularly magnesium hydroxide, calcium carbonate, sodium carbonate and sodium bicarbonate. pH profile and the binding efficacy of final formulation was evaluated in simulated gastric fluid (SGF). Methods The capsule formulation was optimized with desired in vitro characteristics. The final formulations (FF1-FF4) were evaluated for drug release, pH profile and binding efficacy for thallium (Tl). The stability studies were performed in terms of drug assay, Fourier transformed infrared (FTIR) spectroscopy and Thermo-gravimetric analysis (TGA). The in vivo study was performed in rats to determine the removal efficacy of optimized formulation (FF4) for Tl. Results The PB formulation consisting of optimized PB granules and pH modifying agents showed significant increase in the binding efficacy for Tl in SGF at equilibrium time of 24h. The Maximum Binding Capacity (MBC) of FF1-FF4 was found to be higher than commercially available Radiogardase®-Cs capsules and PB granules alone in SGF. The blood Tl level in rats treated with FF4 showed three-fold decreases in level of Tl in blood (Cmax) and Area under Curve (AUC) as compared to control. Conclusion The results revealed that the developed oral PB formulation has a significantly higher efficiency of binding Tl at acidic pH of the stomach thereby reducing its absorption into the systemic circulation. Thus, the optimized formulation of PB with pH modifying agents is a better drug for prophylactic use in thallium ingestion. Graphical Abstract
- 1 February 2023
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 49 (2) , 149-158
Oral formulation of Prussian blue with improved efficacy for prophylactic use against thallium
Objective The present study is aimed to enhance the efficacy of Insoluble Prussian blue (PB) in stomach. PB formulation was developed comprising of PB in combination with pH modifying agents particularly magnesium hydroxide, calcium carbonate, sodium carbonate and sodium bicarbonate. pH profile and the binding efficacy of final formulation was evaluated in simulated gastric fluid (SGF). Methods The capsule formulation was optimized with desired in vitro characteristics. The final formulations (FF1-FF4) were evaluated for drug release, pH profile and binding efficacy for thallium (Tl). The stability studies were performed in terms of drug assay, Fourier transformed infrared (FTIR) spectroscopy and Thermo-gravimetric analysis (TGA). The in vivo study was performed in rats to determine the removal efficacy of optimized formulation (FF4) for Tl. Results The PB formulation consisting of optimized PB granules and pH modifying agents showed significant increase in the binding efficacy for Tl in SGF at equilibrium time of 24h. The Maximum Binding Capacity (MBC) of FF1-FF4 was found to be higher than commercially available Radiogardase®-Cs capsules and PB granules alone in SGF. The blood Tl level in rats treated with FF4 showed three-fold decreases in level of Tl in blood (Cmax) and Area under Curve (AUC) as compared to control. Conclusion The results revealed that the developed oral PB formulation has a significantly higher efficiency of binding Tl at acidic pH of the stomach thereby reducing its absorption into the systemic circulation. Thus, the optimized formulation of PB with pH modifying agents is a better drug for prophylactic use in thallium ingestion. Graphical Abstract
- 13 June 2022
- Published by Springer Nature in Archives of Microbiology
- Vol. 204 (7) , 1-10
Quantitative evaluation of mercury adsorption and removal efficacy of Spirulina (Arthrospira platensis) powder in mice
Spirulina is a blue-green alga, grown in alkaline water and used for detoxification of several toxic metal ions. Apart from its nutritional value, it is also used for the decontamination of toxic metal ions. Therefore, present study was envisaged to evaluate the adsorption and removal efficiency of Spirulina powder for mercury. The adsorption efficiency of Spirulina was evaluated in terms of weight of adsorbent, contact time, simulated gastric (SGF) and intestinal (SIF) fluid, and mercury concentration. In vivo removal efficacy of Spirulina for mercury was evaluated in mice. The mercury content in major tissues, urine and feces was estimated. The whole tissue retention and excretion of mercury after treatment with Spirulina were taken as a measure of its metal ions removal efficacy. Activated charcoal was taken as a standard adsorbent for comparative study. The maximum adsorption capacity of Spirulina and charcoal for mercury was found to be 66.667 and 158.730 mg g−1 in water, 83.33 and 94.340 mg g−1 in SGF and 125.0 and 133.33 mg g−1 in SIF, respectively. In mice, Spirulina and activated charcoal were significantly reduced the mercury deposition in tissues and facilitated their excretion through feces. Spirulina has shown good adsorption and removal efficacy like activated charcoal. Therefore, Spirulina can be used as a potential adsorbent to remove mercury from the body.
- 13 June 2022
- Published by Springer Nature in Archives of Microbiology
- Vol. 204 (7) , 1-10
Quantitative evaluation of mercury adsorption and removal efficacy of Spirulina (Arthrospira platensis) powder in mice
Spirulina is a blue-green alga, grown in alkaline water and used for detoxification of several toxic metal ions. Apart from its nutritional value, it is also used for the decontamination of toxic metal ions. Therefore, present study was envisaged to evaluate the adsorption and removal efficiency of Spirulina powder for mercury. The adsorption efficiency of Spirulina was evaluated in terms of weight of adsorbent, contact time, simulated gastric (SGF) and intestinal (SIF) fluid, and mercury concentration. In vivo removal efficacy of Spirulina for mercury was evaluated in mice. The mercury content in major tissues, urine and feces was estimated. The whole tissue retention and excretion of mercury after treatment with Spirulina were taken as a measure of its metal ions removal efficacy. Activated charcoal was taken as a standard adsorbent for comparative study. The maximum adsorption capacity of Spirulina and charcoal for mercury was found to be 66.667 and 158.730 mg g−1 in water, 83.33 and 94.340 mg g−1 in SGF and 125.0 and 133.33 mg g−1 in SIF, respectively. In mice, Spirulina and activated charcoal were significantly reduced the mercury deposition in tissues and facilitated their excretion through feces. Spirulina has shown good adsorption and removal efficacy like activated charcoal. Therefore, Spirulina can be used as a potential adsorbent to remove mercury from the body.